With presence in four countries and over 18 years in the field of biologic drug discovery, Somata Genesis pioneers therapeutic applications that combine modern administration techniques with cells and cytokines to overcome disease and injury.

Somata Genesis, Inc. is the first company to establish collaborative associations within the US health insurance circle and OHRP oversights to receive Phase II clinical trial coverage for its MS drug Neutrojen M-150 under provisions of the Right to Try Act 2018.

Somata Genesis Biotech Pvt. Ltd. leverages India’s cost-effective clinical research and diverse manufacturing pool to constantly improve its formulations and engage highly experienced Indian surgeons and scientists to develop and deliver clinical protocols achievable nowhere else in the world. At present the company is building an all-in-one research and medical facility on the scenic west coast of India.

About the founder

Surjo Banerjee, founder of Somata Genesis entered clinical research with a vision to overcome the most challenging areas of modern medicine where only symptomatic suppression exist. With focus on cerebral issues rooted in insufficiency, Banerjee explored vascular links to neurological problems and later used his findings to develop methods to restore function in aging and impacted tissue.